Reported Earlier, Mesoblast Posts Q4 Ryoncil Revenue Of $36M, Full-Year Cash Spend Of $43.8M, And $103M Cash Balance At June 30, 2026
Share
Why It Matters
Mesoblast sold $36 million of its medicine Ryoncil in the last three months and has $103 million in the bank. When you look at this company, watch whether sales keep growing and how fast they're spending money.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.